Occam Places Gates Foundation Leader as CEO at Variant Bio
Variant Bio is an early stage, Lux-backed, genomics-based drug development company leveraging insights derived from studying outlier populations to discover new medicines.
Andrew Farnum comes to Variant from The Bill & Melinda Gates Foundation where he spent the last eight years running global investments responsible for what is now a $2 billion impact investing vehicle focused on the global healthcare objectives.
In Farnum, Variant has captured a leader with a global perspective as well as a true desire to further the betterment of mankind. Andrew is also a talented investment executive, and somebody who has learned how to manage smaller organizations.
In summary, Farnum possesses charisma, perspective, intellectual curiosity, an elevated ethical posture, and knowledge of the venture world, assets that will serve him and Variant well as the organization seeks to execute on its global mission of discovering novel therapeutics to address major unmet medical needs of patients across the world.
Recent Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.